Relmada Therapeutics (RLMD) Reports Q4, Provides Corporate Update
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics, Inc. (Nasdaq: RLMD) today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended
"Following the availability of top-line results in the Reliance I (Study 301), one of two Phase 3 sister two-arm, placebo-controlled, pivotal studies evaluating REL-1017 25mg as a potential adjunctive treatment for major depressive disorder (MDD), in
"We are confident that we have an approvable drug and need to focus on clinical trial execution to accomplish this," continued
Recent Corporate Highlights
- Analyzed full data set and final study report for Study 301 to identify key insights to be leveraged in continued development of REL-1017 for the adjunctive treatment of MDD
- Based on the primary and pre-specified analyses from Study 301, the Company believes the signal of REL-1017's efficacy is clear and warrants continued development
- Implementing critical changes to ongoing Study 302, for which a protocol amendment has been finalized, and initiating one new trial, Study 304, for which the protocol has been drafted and will be ready to enroll by mid-2023
- Appointed CNS therapeutics expert
Cedric O'Gorman , M.D., as Chief Medical Officer to lead medical, clinical, and regulatory functions in support of the Company's late-stage REL-1017 development program - Appointed
Fabiana Fedeli , Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of theUnited Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors
Upcoming Anticipated Milestones for REL-1017
- Complete enrollment in ongoing Study 302, which is planned to enroll approximately 300 patients, in the first half of 2024
- Initiate Study 304, as adjunctive treatment for MDD, in mid-2023, with a planned enrollment of approximately 300 patients, with completion anticipated in the second-half of 2024
- Complete study 310, the open-label study, with data in mid-2023
Fourth Quarter 2022 Financial Results
- Research and development expense for the three months ended
December 31, 2022 , totaled$26.9 million , compared to$25.3 million for the three months endedDecember 31, 2021 . The increase was primarily driven by an increase in stock-based compensation costs. - General and administrative expense for the three months ended
December 31, 2022 , totaled$11.8 million compared to$8.9 million for the three months endedDecember 31, 2021 , an increase of approximately$2.9 million . The increase was primarily driven by an increase in stock-based compensation costs. - The net loss for the three months ended
December 31, 2022 , was$37.9 million , or$1.28 per diluted share, compared with a net loss of$34.4 million , or$1.80 per diluted share, for the three months endedDecember 31, 2021 .
Full-Year 2022 Financial Results
- Research and development expense for the year ended
December 31, 2022 , totaled$113.3 million , compared to$90.6 million for the year endedDecember 31, 2021 . The increase was primarily driven by increased costs associated with preparing and conducting RELIANCE, the Company's Phase 3 program for REL-1017. - General and administrative expense for the year ended
December 31, 2022 , totaled$47.9 million , compared to$35.1 million for the year endedDecember 31, 2021 . The increase was primarily driven by an increase in stock-based compensation. - Net loss for the year ended
December 31, 2022 and 2021 was$157.0 million and$125.8 million , respectively. The Company had a net loss of$5.30 and$7.16 per share for the year endedDecember 31, 2022 and 2021, respectively. - As of
December 31, 2022 , the Company had cash, cash equivalents, and short-term investments of approximately$148.3 million , compared to cash, cash equivalents, and short-term investments of approximately$211.9 million atDecember 31, 2021 .
Conference Call and Webcast Details
Toll Free: | 877-407-0792 |
International: | 201-689-8263 |
Conference ID: | 13735262 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1591728&tp_key=cb7f04a9a4 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Visa (V) earnings and revenue exceed estimates in Q2, shares rise
- Avangrid (AGR) Tops Q1 EPS by 19c
- General Motors (GM) CFO: Expect to return to profits in Q2 in China
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Management CommentsRelated Entities
Earnings, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!